Paper - WANFANG MED ONLINE

You Position: Home > Paper

Detection of ALK and ROS1 fusion gene in lung adenocarcinomas patients and its clinical significance

( views:699, downloads:97 )

Author:: No author available

Journal Title:: 国际呼吸杂志

Issue:: 22

DOI:: 10.3760/cma.j.issn.1673-436X.2016.22.002

Key Word:: 肺腺癌;ALK;ROS1;荧光原位杂交;Lung adenocarcinoma;ALK;ROS1;Fluorescent in situ hybridization

Abstract： Objective To explore the frequency of ALK and ROS1 fusion genes in lung adenocarcinomas and its correlation with clinicopathologic features.Methods ALK and ROS1 fusion genes from samples of 332 patients with lung adenocarcinomas were detected by fluorescence in situ hybridization.The relationship between ALK,ROS1 fusion genes and clinicopathologic features was analyzed.Results ALK fusion gene was detected in 28 of 332 lung adenocarcinomas samples (8.4%). There was statistical difference in the gender,age,smoking history and clinical stage of patients.1 3 patients with ROS1 fusion gene were identified among the 332 lung adenocarcinomas samples,which was not correlated with the gender,age,smoking history and clinical stage of patients.None of the cases had concurrent ALK and ROS1 fusion.Conclusions The gene fusion rates of ALK and ROS1 are low in lung adenocarcinomas,and may be defined as special molecular subtype.ALK and ROS1 fusion genes occur more frequently in younger and non-smoking female patients with advanced stage.Genetic testing has important significance to guide clinical targeted therapy.

Reference

[1]Takeuchi,K.,Soda,M.,Togashi,Y.,etc.RET, ROS1 and ALK fusions in lung cancer[J].2012,18(3).
[2]Manabu, Soda,Young Lim, Choi,Munehiro, Enomoto,etc.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.[J].2007,448(7153).
[3]Maemondo,M.,Inoue,A.,Kobayashi,K.,etc.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].2010,362(25).
[4]Shaw AT,Yeap BY,Solomon BJ,etc.Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.[J].2011,12(11).
[5]Zhou, Jianya,Zhao, Jing.Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening.[J].2014,9(3).
[6]Soo,R.A.,Ou,S.-H.I.,Yen,Y.,etc.ROS1 as a 'druggable' receptor tyrosine kinase: Lessons learned from inhibiting the ALK pathway[J].2012,12(4).
[7]Rimkunas,V.M.,Crosby,K.E.,Li,D.,etc.Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: Identification of a FIG-ROS1 fusion[J].2012,18(16).
[8]Rodig SJ,Dacic S,Mino Kenudson M.Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.[J].2009,15(16).
[9]Ying Li.Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer.[J].2013,8(1).
[10]Ryu Jokoji,Yasushi Sakamaki,Masahiko Tsujimoto,etc.Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma[J].2010,63(12).
[11]Kim, H. R.,Lim, S. M.,Kim, H. J.,etc.The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma[J].2013,24(9).
[12]Wang, Jinghui,Cai, Yiran,Dong, Yujie,etc.Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements Detected by FISH, IHC, and RT-PCR.[J].2014,9(7).
[13]Guo A,Haack H,Nardone J,etc.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer[J].2007,131(6).
[14]J?anne,P.A.,Gandhi,L..Crizotinib for ALK-rearranged non-small cell lung cancer: A new targeted therapy for a new target[J].2012,18(14).
[15]Ueno T,Choi YL,Okumura S,etc.KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.[J].2009,15(9).
[16]Maher Albitar,Jay A Scheerle,Constance Novick,etc.Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer.[J].2011,204(1).
[17]Katayama,R.,Bergethon,K.,Lovly,C.M.,etc.ROS1 rearrangements define a unique molecular class of lung cancers[J].2012,30(8).
[18]J Guillermo, Paez,Pasi A, J?nne,Jeffrey C, Lee,etc.EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.[J].2004,304(5676).
[19]Clark,J.W.,Costa,D.B.,Maki,R.G.,etc.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer[J].2010,363(18).
[20].Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib[J].2013,81(1).
[21]W Cai,X Li,C Zhou,etc.ROS1 fusions in Chinese patients with non-small-cell lung cancer.[J].2013,24(7).
[22]Davies,K.D.,Le,A.T.,Theodoro,M.F.,etc.Identifying and targeting ROS1 gene fusions in non-small cell lung cancer[J].2012,18(17).
[23]Yasuda,H.,DeFigueiredo-Pontes,L.L.,Kobayashi,S.,etc.Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer[J].2012,7(7).